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Abstract In the present study, chitosan and polyvinyl alcohol (PVA) were blended with different concentrations of
sodium montmorillonite (Na?MMT) clay solution by a solvent casting method. X-ray diffraction and transition electron
microscope results show that the film properties are related to the co-existence of Na?MMT intercalation/exfoliation in the
blend and the interaction between chitosan–PVA and Na?MMT. 5-Fluorouracil (5-FU) was loaded with chitosan–PVA/
Na?MMT nanocomposite films for in vitro drug delivery study. The antimicrobial activity of the chitosan–PVA/Na?MMT
films showed significant effect against Salmonella (Gram-negative) and Staphylococcus aureus (Gram-positive), whereas
5-FU encapsulated chitosan–PVA/Na?MMT bio-nanocomposite films did not show any inhibition against bacteria. Our
results indicate that combination of a flexible and soft polymeric material with high drug loading ability of a hard inorganic
porous material can produce improved control over degradation and drug release. It will be an economically viable method
for preparation of advanced drug delivery vehicles and biodegradable implants or scaffolds.
Keywords Biopolymer  Chitosan–PVA/Na?MMT  Montmorillonite  5-Fluorouracil  Drug release  Antimicrobial
activity
1 Introduction
In the past few decades, drug delivery systems have been of
great interest and resulted in many efforts to realize the
effectiveness and targeted drug delivery tendency as well
as to reduce the associated side effects. Controlled drug
delivery system is necessary in order to develop new nano-
medicines. Thus, the carriers used for drug release are
generally biodegradable polymers [1] and hard inorganic
porous matrices [2]. In recent past, biodegradable polymer
attracted much attention owing to its potential applications
as a carrier in drug delivery systems.
Chitosan is a semi-crystalline and linear polysaccharide
composed of (1–4)-2-acetamido-2-deoxy-b-D-glucan (N-
acetyl D-glucosamine) and (1-4)-2-amino-2-deoxy-b-D-
glucan (D-glucosamine) units. It is not widely present in the
environment but can be easily obtained from the partial
deacetylation of a natural polymer chitin [3]. The
deacetylation degree of chitosan provides valuable infor-
mation regarding to the number of amino groups (–NH2)
along the chains and it can be measured as the ratio of D-
glucosamine to the sum of D-glucosamine and N-acetyl D-
glucosamine. For a chitosan, the deacetylated chitin must
have at least 60 % of D-glucosamine residues [4] and
controlled by chemical hydrolysis under harsh alkaline
conditions or enzymatic hydrolysis in the presence of
particular enzymes among of chitin deacetylase [5]. The
presence of amino groups in the chitosan structure differ-
entiates the chitosan from chitin and allows this polymer to
have several unique properties. Undoubtedly, the amino
& A. Babul Reddy
ababulreddy@gmail.com
1 Department of Chemical, Metallurgical and Materials
Engineering, Tshwane University of Technology, CSIR
Campus, Building 14D, Lynwood Ridge,
Private Bag X025, Pretoria 0040, South Africa
2 Department of Food Process Engineering, School of
Bioengineering, SRM University, Kattankulathur,
Tamil Nadu 603203, India
123
Nano-Micro Lett. (2016) 8(3):260–269
DOI 10.1007/s40820-016-0086-4
groups of the D-glucosamine residues might be protonated,
when it is soluble in aqueous acidic solutions (pH\ 6).
Whereas the applications of chitin are tremendously lim-
ited due to its weak solubility in water or other organic
solvents. Interestingly, the aqueous acidic solubility of
chitosan is pH dependent, permitting its processability
under warm conditions, which opens the door for many
applications, particularly in the field of pharmaceutical and
cosmetics [3]. This polysaccharide has been extensively
studied in the field of biomaterials because of its
biodegradability, biocompatibility, and biological proper-
ties. Among various polymer development processes,
polymer blending is one of the most economical and rapid
ways to innovate novel materials with vital properties and
it has made great scientific and commercial progresses [6].
Polyvinyl alcohol (PVA)-based nanocomposites are one
of the familiar polymer composites that have been used in
various biomedical applications (implants, artificial organs,
contact lenses, drug delivery devices, wound dressings,
etc.) due to its good biocompatibility behavior [7–11].
There are numerous methods available for crosslinking
PVA chains to synthesize PVA composites, including bulk
mixing with crosslinking agents such as glutaraldehyde
(GA), freezing–thawing cyclic process [12], as well as
electron beam irradiation [13].
Nowadays increased attention has been focused on drug
intercalated smectites, particularly montmorillonite (MMT)
pharmaceutical grade mineral clay [14, 15]. MMT has
cation exchange capacity, good adsorption capacity, large
specific surface area, and drug-carrying ability. It is
hydrophilic and highly dispersible in water and can aid in
the synthesis of a wide variety of hydrophilic and proto-
nated organic molecules, which can be released in con-
trolled fashion by replacement with other types of cations
in the drug release processes [16–18]. Therefore, MMT is a
good delivery carrier of hydrophilic drugs due to its high
aspect ratio and can afford mucoadhesive ability for the
nanoparticles to cross the gastrointestinal barrier [19, 20].
So far, MMT has been used as a controlled release system
and proved to be nontoxic by hematological, biochemical
and histopathological analyses in rat models [21]. It is also
utilized as a sustained release carrier for various thera-
peutic molecules, such as 5-fluorouracil (5-FU) [22], ser-
traline [23], vitamin B1 [14, 15], promethazine chloride
[24], and buspirone hydrochloride [25].
5-FU is an effective chemotherapy option available for
the treatment of colorectal cancer [26, 27], stomach cancer
[27], breast cancer [28], brain tumor [29, 30], liver cancer
[31], pancreatic cancers [32–34], and lung cancer [35–38].
It is a pyrimidine analog that restrains the biosynthesis of
deoxyribonucleotides for DNA replication through con-
straining thymidylate synthase activity, resulting to thy-
midine exhaustion, incorporation of deoxyuridine
triphosphate into DNA and subsequently causing cell death
[39–41]. However, 5-FU has limitations, such as short
biological half-life due to rapid metabolism, non-uniform
and incomplete oral absorption owing to metabolism by
dihydropyrimidine dehydrogenase [42–45], toxic side
effects on bone marrow and gastrointestinal tract, and non-
selective action against healthy cells [46]. For successful
cancer treatment, overcoming the toxic side effects on bone
marrow is highly essential, which might possibly be
achieved by the control release of the drug by intercalated
in the clay interlayer and biopolymeric systems.
However, no report is available in the literatures for
combination of biodegradable polymer chitosan–PVA and
Na?MMT for controlled release of 5-FU. In this study, we
have tried to develop a biodegradable and biocompatible
polymer to control drug release properties with pharma-
ceutical grade MMT in order to produce oral and controlled
drug delivery formulations for 5-FU. Being a highly
hydrophilic drug molecule, it is very difficult to encapsu-
late high amount of 5-FU within the hydrophilic polymer
matrix. Therefore, in the present study, the modified sol-
vent casting method has been developed to entrap sub-
stantial amount of drug in the synthesized formulations.




High molecular weight chitosan (viscosity of between 800
and 2000 cps), PVA (96 % hydrolysed, molecular weight
85,000–145,000, and the degree of deacetylation higher
than 75 %), and 5-FU (99 %) were sourced from Sigma-
Aldrich (South Africa). GA, sodium chloride (NaCl),
sodium hydroxide (NaOH), silver nitrate (AgNO3), acetic
acid (CH3COOH), and de-ionized water were supplied by
Merck. Na?MMT was supplied as powder by Southern
Clay Products, Inc. (Texas, USA). The Department of
Microbiology (SRM University, India) provided the stan-
dard cultures of the organisms. All the chemicals and
reagents were used without further purification. Double-
distilled water was used for the preparation of all solutions.
2.2 Solutions Preparation
50 mL of chitosan solution (1 % wt/v in acetic acid) and
50 mLof PVA solution (1 %wt/v inwater) (1:1)weremixed
together in a 250 mL beaker and stirred at room temperature
until a homogeneous solution was obtained. Then, different
amounts of Na?MMT (1–5 wt%) nanoparticles were added
to abovemixture and stirring was continued for a further 6 h.
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Before casting, 1 mL of 2 % GA solution in water (a cross-
linking agent) was added under stirring at room temperature.
The solution was transferred immediately into Petri dishes
(10 mm 9 10 mm) and dried at room temperature. The
formed cross-linked chitosan–PVA/Na?MMT films were
washed with double-distilled water for neutralization and
dried at room temperature [47, 48].
2.3 Swelling Studies
Swelling studies were carried out according to the report of
Vimala et al. [48]. The dried pre-weighed films were
equilibrated in 250 mL phosphate buffer (pH 7.4) at 25 C
for 24 h and then water up-take of the films was measured
for every 30 min using an analytical balance. The swelling
ratio (Q) of the films was calculated using Eq. 1,
Q ð%Þ ¼ Ws Wd
Wd
 100; ð1Þ
where Ws is the weight of the swollen film at different time
intervals and Wd is the weight of the dry film.
2.4 Characterization
Bruker D8 advanced refractometer X-ray diffraction
(XRD) was used to determine the intercalation or exfolia-
tion (or both) of nanocomposite films. Transition electron
microscope (TEM) images were recorded using a Tecnai F
12 JEOL-JEM 2100 at an accelerating voltage of 15 kV.
The morphologies of the bio-nanocomposite films were
observed by scan electron microscopy (SEM, JEOL
FESEM JSM-7600F) equipped with energy-dispersive
X-ray spectroscopy. Fourier transform infra-red (FTIR)
spectroscopy measurement was carried on Perkin-Elmer
UATR two using diamond Zn/Se plate. Small amount of
sample was pressed on a Zn/Se plate and the spectra were
recorded over a range of 550–4000 cm-1. Thermal studies
of the films were carried out using TGA 7 instrument
(Perkin-Elmer) at a heating rate of 10 C min-1 under a
constant nitrogen flow of 20 mL min-1.
2.5 5-Fluorouracil Loading and Encapsulation
Efficiency
5-FU was loaded into the chitosan–PVA/Na?MMT
nanocomposite films by the swelling method. The films
(100 mg) were allowed to swell in 40 mL 5-FU solution
(5 mg 5-FU, 8 mL acetone and 12 mL distilled water) for
24 h at 25 C. The loading efficiency of 5-FU in the
nanocomposite films was determined spectrophotometri-
cally [39, 48]. The drug-loaded films were placed in 50 mL
phosphate buffer solution and stirred vigorously for 4 days
in order to extract the drug from the films. The solution was
filtered and assayed using UV spectrophotometer at fixed
kmax value of 266 nm. The results of the drug loading and
encapsulation efficiency were calculated using Eqs. 2 and
3, respectively.
Drug releasing
















Fig. 1 Schematic representation for the formation of 5-FU loaded chitosan/PVA–Na?MMT nanocomposites
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Drug loading ð%Þ
¼ Weight of drug in filmWeight of the film
Weight of the film
 100;
ð2Þ




2.6 Release of 5-FU
For the control release studies of 5-FU from the loaded
nanocomposite films, known weights were placed in a
measured volume (50 mL) of 7.4 pH phosphate buffer
solution at room temperature and the released amount of
5-FU was determined at different time intervals by
recording the absorbance of the release medium using the
UV–vis spectrophotometer [48]. The recorded absorbance
was then related to the amount of 5-FU released using a
calibration plot. The absorption of the solutions of 5-FU
was measured at kmax value of 266 nm.
2.7 Antimicrobial Activity
The antibacterial activity of the nanocomposites was
investigated by a disk method and the standard procedure
was described elsewhere [49]. Nutrient agar medium was
prepared by mixing peptone (5.0 g), beef extract (3.0 g),
and sodium chloride (NaCl, 5.0 g) in 1000 mL distilled
water and the pH was adjusted to 7.0. Finally, agar (15.0 g)
was added to the solution. The agar medium was sterilized
in an autoclave at a pressure of 6.8 kg m-2 (15 lbs) for
30 min. This medium was transferred into sterilized Petri
dishes in a laminar air flow chamber (Microfilt Laminar
Flow Ultra Clean Air Unit, Mumbai, India). After solidi-
fication of the media, bacteria (Salmonella, Staphylococcus
aureus, Streptococcus mutants and Escherichia coli) (50
lL) culture were spread on the solid surface of the media.
Over the inoculated Petri dish, one drop of gel solution
(20 mg/10 mL distilled water) was added using a 10 lL tip
and the plates were incubated for 48 h at 37 C.
3 Results and Discussion
The physical status of Na?MMT and chitosan–PVA in the
synthesized chitosan–PVA/Na?MMT nanocomposite was
studied with the help of XRD. The characteristic diffraction
peak of pristine Na?MMT is appeared at 7.2, corre-
sponding to the (001) plane with a d-spacing of 12.1 A˚ (see
Fig. 2a). An decrease in the intensity of the (001) plane
along with a shift in the 2h value from 7.2 to 7.0 was
observed in the case of chitosan–PVA/Na?MMT
nanocomposites (1 wt% clay; see Fig. 2b). The hump in the
background from 18 to 24 is due to the presence of a
polymer within the chitosan–PVA/Na?MMT nanocom-
posites. According to Bragg’s law, a shift in 2h value from
higher diffraction angle to lower diffraction angle is
indicative of an increase in d-spacing [14, 15, 25]. The d-
spacing data from 12.1 to 14.4 A˚ are given in Table 1. The
increase of 2.15 A˚ is attributed to the co-existence of
intercalation/exfoliated of chitosan–PVA within the Na?-
MMT. This is further supported by the HRTEM image (see
Fig. 3) in which the presence of expanded and uniformly
spaced Na?MMT layers in the chitosan–PVA is shown
clearly. These results confirm that the Na?MMT resides in
or entered into the chitosan–PVA matrices [50].
The TEM image of nanocomposite (5 wt% Na?MMT) is
illustrated in Fig. 3. The images show typical morphology
of layered materials, in which the dark lines correspond to
Na?MMT clay layers, while bright areas represent the
chitosan–PVA polymer matrices. As seen in Fig. 3, the
interlayer distance of clay was obviously enlarged, fol-
lowing the addition of the mixture of chitosan–PVA
polymers. Moreover, as seen from the higher magnification
image (100 nm), layered silicates were exfoliated and
uniformly dispersed in chitosan–PVA polymer matrices at
nano-level and it is supported from the XRD patterns.
SEM images of the nanocomposite films are shown in
Fig. 4. As seen in the figure, the surface roughness of the
films was enhanced by increasing the Na?MMT content.
Furthermore, there is a uniform surface roughness observed
for 5 wt% Na?MMT films. The possible reason is that the
polycation ability of the matrix was attracted to the nega-
tive ability of clay and resulted in a physical bond (hy-
drogen bond) form between them. Such exfoliated structure
was confirmed in above XRD measurements and it was
also observed by Rhim et al. [49].
FTIR spectroscopy depicted in Fig. 5 was used to
identify the chemical groups of polymers. From the spec-
trum of neat chitosan, the absorption peaks around the
wave number of 3900 and 1405 cm-1 could be ascribed to
the stretching and bending vibrations of the –NH or –OH
groups. The peaks around 905 and 1560 cm-1 correspond
to saccharide structure [51]. However, in the case of
Na?MMT, the four types of vibrations are exhibited at
3640, 1668, 997, and 516 cm-1 and they are ascribed to
Si–O and OH bonds, which is in good agreement with other
report [50]. The spectra of the nanocomposite films include
major characteristic peaks of chitosan, PVA, and Na?-
MMT. The peak around 3320 cm-1 is relevant to the
overlapping of the –NH and –OH stretching vibrations in
chitosan and PVA. Major absorptions at 425 and 524 cm-1
were observed in the spectra of pure Na?MMT and chi-
tosan–PVA/Na?MMT 1–5 %, while these peaks are absent
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in the spectrum of neat chitosan–PVA films (not included
here). These results is an evidence of the presence of
Na?MMT nanoclays inside the chitosan–PVA matrices.
The swelling ability of antibacterial nanocomposite
films plays a significant role in their wound healing
capacity and antibacterial activity in their biomedical
applications due to their high water clenching capacity
[48]. They can further absorb a significant amount of the
wound exudates by swelling in fast curing of the wound.
Figure 6a shows the swelling capacity as a function of time
of the nanocomposite films developed in this study. The 5
wt% Na?MMT film shows the highest swelling capacity
than other films. This may be due to the intermolecular
interaction between water molecules in clay galleries and
the lone pair electrons of –NH2 and –OH groups present in
chitosan–PVA chains.
Drug release behavior of chitosan–PVA/Na?MMT films
was also studied in PBS solution of pH 7.4. Figure 6b
shows the % cumulative drug release behavior of the
nanocomposites. It can be observed that the loading effi-
ciency increases with increasing clay content from 1 to 5
wt% (see Table 2). This excessive increase of encapsula-
tion may be attributed to the cationic nature of 5-FU (–NH
group turn into –NH? while dissolving in water) in the































Fig. 2 XRD patterns of Na?MMT and chitosan–PVA/Na?MMT nanocomposite films with Na?MMT ranging from 1 to 5 wt%
Table 1 XRD data of Na?MMT and chitosan/PVA–Na?MMT
nanocomposite films
Specimen IDs 2h () d-spacing (A˚)
Na?MMT 7.25 12.1
1 wt% clay 7.05 12.5
2 wt% clay 6.95 12.7
3 wt% clay 6.78 12.9
4 wt% clay 6.42 13.8
5 wt% clay 6.12 14.4
Fig. 3 TEM images of an intercalated/exfoliated chitosan–PVA/Na?MMT nanocomposite (4 wt% Na?MMT)
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5-FU with negatively charged Na?MMT and chitosan–
PVA polymer matrices, resulting in high encapsulation
efficiency [52]. Therefore and correspondingly so, the
release efficiency of 5-FU from nanocomposite films also
increases with increasing the clay content.
However, in order to support above statements, we
compare the SEM morphology of nanocomposite films
before and after drug release. As shown in Fig. 7, 5-FU-
loaded film shows very smooth surface, which may be due
that 5-FU entered and sit on between clay galleries. In
contrast, after the drug release from nanocomposite, very
clear holes appear on the surface of the matrix. This is an
evidence that 5-FU was released in a control manner from
matrix.
TGA curves of selected samples are shown in Fig. 8. It
can be seen that Na?MMT shows 10 % weight loss below
100 C due to the loss of water molecules. The
nanocomposite films have higher thermal response than
those of the neat chitosan, PVA or blended film. The onset
temperature for decomposition shifts towards higher tem-
peratures as the clay loading increases. This is because the
presence of the clay immobilizes the polymer chains and
Fig. 4 SEM images of chitosan–PVA/Na?MMT nanocomposite films with different Na?MMT contents
Na+MMT
1 668





















Fig. 5 FTIR spectra of neat chitosan, Na?MMT, and chitosan–PVA/
Na?MMT nanocomposite films with different Na?MMT contents
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free radicals formed during the degradation process (thus
slowing down this process), or the presence of clay hinders
the diffusion of volatile products through the nanocom-
posites (thus retarding the mass loss from the nanocom-
posites during degradation [53]). The increase in the
thermal stability can also be attributed to the restricted
thermal motions of the polymer chains inside the clay
galleries [54].
Antimicrobial activity of Na?MMT-containing chi-
tosan–PVA films were tested against Salmonella, S. aureus,
E. coli and S. mutants. Figure 9 shows the characteristic
test results of nanocomposite films by a disk-diffusion
method. The antimicrobial activity determined by the
diameter of the growth inhibition zone was dependent on
the test nanocomposite film. The tests on all samples were
repeated using four other microorganisms. Generally, chi-
tosan and chitosan/Na?MMT nanocomposite films did not
show clear microbial inhibition zones [49], whereas chi-
tosan–PVA/Na?MMT nanocomposite films exhibited dis-
tinctive microbial inhibition zones against two test
microorganisms (Salmonella and S. aureus) in the disk
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Fig. 6 a Swelling capacity of chitosan–PVA/Na?MMT nanocomposite films with different Na?MMT contents. b 5-Fluorouracil release profile
from nanocomposite films with different Na?MMT contents
Table 2 Drug loading
efficiency of chitosan/PVA–
Na?MMT nanocomposite films
Specimen IDs Weight of
the film (mg)




1 wt% clay 100 135 35
2 wt% clay 100 141 41
3 wt% clay 100 153 53
4 wt% clay 100 158 58
5 wt% clay 100 165 65
mlifdesaelerUF-5(b)mlifdedaolUF-5(a)
Fig. 7 SEM images of chitosan/PVA–Na?MMT nanocomposites film before and after 5-FU release
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antimicrobial activity due to its cationic property [49]. This
apparently different result for chitosan film is mainly due to
the limits of detection of antimicrobial activity when using
the disk method [49]. The appearance and size of the clear
zone in the disk method are mainly dependent on the ratio
of disk area and size of contact area, inoculum, and type of
solid medium. Of interest, Na?MMT-incorporated
nanocomposite film exhibited antimicrobial activity against
the two bacteria, Salmonella and S. aureus, but did not
show any antimicrobial activity against S. mutants and
E. coli. Therefore, the present nanocomposite films
exhibited antimicrobial activity against Gram-positive and
Gram-negative bacteria. Furthermore, in the present study,
the addition of Na?MMT to the formulations slightly
condensed the antimicrobial effect of the nanocomposite
films. This may be ascribed to the high cross-linking level
of chitosan–PVA/Na?MMT nanocomposites that inter-
cepts the diffusion of the 5-FU drug through the agar
medium. On the other hand, weak inhibition of S. aureus
growth was observed by 5 wt% clay loading nanocom-
posite film, having higher concentration of Na?MMT that
is maybe due to higher rate of 5-FU drug diffusion. This is
in good agreement with the data mentioned in the drug
release section, indicating formulations with high clay
content exhibited higher rate of drug release in the disso-
lution medium than those with low content of clay [50, 55].
4 Conclusions
Bio-nanocomposite films-based chitosan–PVA/Na?MMT
were developed by a simple solution casting technique. It
was found that the biodegradable polymer was successfully
intercalated into clay galleries. Drug loading efficiency of
chitosan–PVA/Na?MMT films increases with increasing
clay content and higher clay content exhibited higher rate
of drug release. Compared with chitosan and chitosan/
Na?MMT nanocomposite films which did not show clear
microbial inhibition zones, chitosan–PVA/Na?MMT
nanocomposite films showed distinctive microbial inhibi-
tion zones against two test microorganisms and exhibited
antimicrobial activity against Gram-positive and Gram-
negative bacteria. The present study is useful in developing
novel antimicrobial agents for applications in wound
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Fig. 8 TGA curve of Na?MMT and chitosan/PVA–Na?MMT
nanocomposite films with different Na?MMT contents
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Fig. 9 Antibacterial activity of chitosan/PVA–Na?MMT nanocomposite films against a Salmonella and b Staphylococcus aureus
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treatment of infections due to the control release ability. In
addition, the chitosan–PVA/Na?MMT nanocomposite
films are a promising material for the development of new
membranes for waste water treatment.
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